Assessing the attitudes to prostate cancer treatment among European male patients

Abstract

OBJECTIVES To understand the attitudes of patients with prostate cancer toward the disease in general and to the use of hormone therapy as treatment; to assess unmet needs in the management of prostate cancer; and to gauge patient receptivity to a potential 6‐month formulation of a luteinizing hormone‐releasing hormone (LHRH) agonist. PATIENTS AND METHODS Face‐to‐face interviews, lasting 50 min on average, were conducted during January and February 2007 with 200 European men who had been diagnosed with prostate cancer. RESULTS Most patients were very satisfied with their physician, particularly with specialists, with 94% of men being satisfied with their expertise and 67% fully trusting the recommended treatment. Therapeutic efficacy was considered the most crucial aspect of treatment, although maintaining their lifestyle during treatment was also considered important (83% of patients). In all, 67% of patients believed that consideration should be given to lifestyle needs when selecting treatment; however, over half (55%) had never raised lifestyle issues with their physicians. Most patients would prefer fewer injections, with 68% (135/200) preferring 6‐monthly injections over 3‐ or 1‐monthly depots. Perceived advantages of 6‐monthly injections include less discomfort/pain, more quality of life, fewer reminders of the disease and more ability to undertake activities without restriction. CONCLUSIONS Patients with prostate cancer are generally very satisfied with their physicians and the information they receive, yet find it difficult to communicate their lifestyle needs. Most patients would prefer 6‐monthly LHRH agonist therapy due to the many advantages associated with fewer injections, including its efficacy in reducing testosterone levels. Improving patients’ willingness to raise lifestyle issues with their physicians, providing more effective patient‐physician communication and less frequent injections might assist in achieving both optimal control of testosterone and optimal management of prostate cancer.

A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient

“…Therefore, we have to listen to patients' expectations and include patients' preferences. For instance, when selecting the most appropriate treatment modality, PCa patients treated with luteinizing hormone-releasing hormone agonists indicated that they would prefer fewer injections [35] . In this case the use of a 6-month formulation of a luteinizing hormone-releasing hormone agonist would clearly have an added value.…”

Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer

“…On the other hand, these visits may provide patients with comfort, reassurance and a sense of control regarding their disease. To the authors' knowledge, only one previous study has explored this topic specifically and it found a strong patient preference for longer treatment intervals using a qualitative research approach [11]. The objective of the current study was to assess patient preference regarding the length of intervals between treatment and/or clinical control.…”

Patient Preference and the Impact of Decision-Making Aids on Prostate Cancer Treatment Choices and Post-Intervention Regret

“…The reality is that patients repeatedly cite their health care providers as their most important source of information, and they rely on their specialist to inform them about management options 10,20 . Patient preferences for the communication of an initial diagnosis rely on the "honesty and expertise" of their doctors.…”